Fight Over Waze? Way
Health Care: Drugs
Protalix BioTherapeutics Inc. (PLX: AMEX)
$5.20 0.00 | 0.00%
05/24/13 - 04:02 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 34.87M | 8.39M | 6.64M | 388.00K |
| Cost of Sales | 4.90M | 3.31M | 5.85M | 1.58M |
| Gross Operating Profit | 29.97M | 5.07M | 790.00K | -1.20M |
| Selling, General, and Administrative Expenses | 9.76M | 6.93M | 6.88M | 7.14M |
| Research & Development | 28.69M | 31.04M | 29.95M | 21.64M |
| Operating Income before D & A (EBITDA) | -8.48M | -32.90M | -36.04M | -29.98M |
| Depreciation & Amortization | 3.69M | 3.63M | 3.13M | 1.99M |
| Interest Income | 0.00 | 2.00K | 968.00K | 529.00K |
| Other Income - Net | 554.00K | 0.00 | 9.20M | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -11.62M | -36.53M | -29.00M | -31.44M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -11.62M | -36.53M | -29.00M | -31.44M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -11.62M | -36.53M | -29.00M | -31.44M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -11.62M | -36.53M | -29.00M | -31.44M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -11.62M | -36.53M | -29.00M | -31.44M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-11.62M | -36.53M | -29.00M | -31.44M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -11.62M | -36.53M | -29.00M | -31.44M |
| Basic EPS from Continuing Ops. | -0.13 | 0.43 | -0.36 | -0.41 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.13 | 0.43 | -0.36 | -0.41 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.13 | 0.43 | -0.36 | -0.41 |
| Basic Normalized Net Income/Share | -0.13 | n.a. | -0.36 | -0.41 |
| EPS fr Continuing Ops. | -0.13 | 0.43 | -0.36 | -0.41 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.13 | 0.43 | -0.36 | -0.41 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.13 | 0.43 | -0.36 | -0.41 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.13 | n.a. | -0.36 | -0.41 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with PLX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSharebuilder
- UserSUPRATRADE HOT STOCKS (BUY ...
- Usergilver Portfolio 1
- UserTop Biotech Short Squeeze P...
- UserEdwin Lee Portfolio 1
Latest PLX Headlines from TheStreet
- PLX July Options Begin Trading 05.20.13 | 04:05 pm
- Protalix BioTherapeutics To Present At The Oppenheimer 14th Annual Israeli Conference 05.08.13 | 07:05 am
- UPLYSO(TM) (alfataliglicerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease 04.29.13 | 07:04 am
- 5 Stocks Under $10 Set to Soar 04.04.13 | 01:04 pm
- Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease 04.02.13 | 07:04 am
- UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease 03.18.13 | 02:03 pm
- Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease 03.07.13 | 08:03 am
- Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013 02.13.13 | 07:02 am
- Protalix BioTherapeutics Reviewing Partnering And Other Alternatives 02.05.13 | 11:02 am
- Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference 02.05.13 | 07:02 am
Press Releases for PLX
- Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase Alfa) For The Treatment Of Gaucher Disease - Business Wire 05.01.12 | 06:05 pm
- FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012 - PR Newswire 12.06.11 | 07:12 am
- Protalix Announces Successful European GMP Audit - PR Newswire 12.01.11 | 02:12 am
- Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease - PR Newswire 11.10.11 | 01:11 am
- Protalix BioTherapeutics To Present At Four Upcoming Conferences - PR Newswire 10.26.11 | 07:10 am
- Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference - PR Newswire 09.21.11 | 07:09 am
- Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference - PR Newswire 09.13.11 | 08:09 am
- Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology - PR Newswire 09.08.11 | 08:09 am
- Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date - PR Newswire 08.17.11 | 07:08 am
- Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial - PR Newswire 08.01.11 | 08:08 am
Partner Headlines for PLX
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem-BCRT Alliance Extended - Analyst Blog - NASDAQ 08.22.12 | 11:08 pm
- Pluristem Gets Green Light in India - Analyst Blog - NASDAQ 08.20.12 | 11:08 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- 6 Biotech Stocks With Huge Potential In May - Seeking Alpha 04.11.12 | 08:04 am
- Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising - Seeking Alpha 02.10.12 | 08:02 am
- Company News for December 7, 2011 - Corporate Summary - Zacks 12.07.11 | 09:12 am
- Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point - Seeking Alpha 12.07.11 | 09:12 am
- Morning Market Losers - Benzinga 12.06.11 | 09:12 am
